INDIANAPOLIS, May 6, 2021 /PRNewswire/ -- With a goal of
integrating data and technology to help streamline diabetes
management, Eli Lilly and Company (NYSE: LLY) signed strategic
international agreements with four companies – DexCom, Inc., Glooko
Inc., myDiabby Healthcare and Roche – to advance connected
solutions and streamline care for people living with diabetes in
markets outside of the United
States. These companies offer unique diabetes management
platforms that will be compatible with Lilly's Tempo
Pen™ (approved in several global markets) and Tempo
Smart Button™ (currently in late-stage development) to
support people with diabetes and healthcare professionals.
The Tempo Pen is a modified version of Lilly's existing
prefilled, disposable insulin pen to which the Tempo Smart Button –
pending CE (Conformité Européenne or European Conformity) marking –
attaches. Through these new agreements, the Tempo Smart Button will
pair with software and/or medical devices offered by Dexcom,
Glooko, myDiabby Healthcare and Roche, with its mySugr app, to
facilitate the integration of personalized data and actionable
insights.
"We're pleased to work alongside these innovative partners who
share our commitment to improving diabetes outcomes by bringing
together medicine and digital solutions for the global diabetes
community," said Marie Schiller,
vice president of product development for Connected Care and
Insulins at Lilly. "Insulin dose logging is often an incomplete
piece of the diabetes management puzzle for people who use insulin
pens and manually track their doses. By integrating data from the
connected insulin pen solutions into widely used compatible
software, including potential future collaborations, we aim to
support improved decision-making for people with diabetes and their
healthcare providers with accurate, real-time data collection.
These solutions may also help address psychological barriers like
fear of hypoglycemia that may negatively impact diabetes
management."
Lilly aims to receive CE mark for the Tempo Smart Button later
in 2021 and will launch the Tempo Pen and Tempo Smart Button in
several international markets following this certification.
"People with diabetes need access to all of the key information
about their condition. For those who use insulin pens, tracking how
much insulin they delivered and the time of the dose and bringing
that information together with glucose data can help them
meaningfully improve their management," said Tadej Battelino, Head
of Endocrinology, Diabetes & Metabolism, UCH Professor, at the
University of Ljubljana. "These
agreements mark a meaningful step towards providing useful tools
that help provide real-time guidance and holistic support to ease
some of the burdens of living with diabetes."
About Diabetes
An estimated 463 million adults
worldwide1 have diabetes. Type 2 diabetes is the most
common type, accounting for an estimated 90 to 95 percent of all
diabetes cases2. Diabetes is a chronic disease that
occurs when the body does not properly produce or use the hormone
insulin.
About DexCom Inc.
DexCom, Inc. empowers people to take
control of diabetes through innovative continuous glucose
monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
patients, caregivers, and clinicians, Dexcom simplifies and
improves diabetes management around the world.
About Glooko Inc.
Glooko is transforming digital
health by connecting people with diabetes and related conditions
and their health care professionals, enabling telehealth,
clinical research, and improved collaboration. The company's
software platforms, Glooko® and diasend®,
empower the management of diabetes and other chronic conditions by
collecting and unlocking the power of data from blood-glucose
meters, CGMs, insulin pumps, connected insulin pens, blood pressure
cuffs, nutrition apps, connected scales and activity trackers –
bringing insights together in one place. Data is easily uploaded –
remotely via app or in-clinic, securely shared, and visualized in
actionable charts and graphs. This creates a solid foundation
enabling collaboration and confident treatment decisions. The
platforms are compatible with over 95% of global diabetes devices,
along with biometric devices, giving people with diabetes and other
chronic conditions and their care teams the freedom of choice. Over
3 million users have benefitted from health data insights using
Glooko's solutions, which are trusted by world leaders in diabetes
and chronic care, and used in 28 countries across 20 languages.
Learn more at glooko.com.
About myDiabby Healthcare
MyDiabby Healthcare is the
leading European software used by diabetes healthcare providers in
order to manage and help their patients with diabetes remotely
thanks to telemonitoring and tele consultation. As the treatment
for diabetes is based on the visualisation of blood glucose and
insulin, our goal is to make it easier for patients to share their
data with their physician. More than 400 hospitals are using
myDiabby Healthcare in France,
Belgium, and Switzerland.
About Roche Diabetes Care and mySugr
Roche Diabetes
Care has been pioneering innovative diabetes technologies and
services for more than 40 years. Being a global leader in
integrated Personalised Diabetes Management (iPDM), Roche Diabetes
Care aims to support people with diabetes and those at risk to
achieve more time in their target ranges and experience true relief
from the daily therapy routines.
Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising
glucose monitoring, insulin delivery systems and digital solutions,
Roche Diabetes Care unites with its partners to create
patient-centred value. By building and collaborating in an open
ecosystem, connecting devices and digital solutions as well as
contextualising relevant data points, Roche Diabetes Care enables
deeper insights and a better understanding of the disease, leading
to personalised and effective therapy adjustments.
Since 2017, mySugr, one of the most popular diabetes management
apps, is part of Roche Diabetes Care. mySugr aims to simplify life
with diabetes and gives people with diabetes the tools, know-how,
and confidence to manage their diabetes therapy and health
outcomes, making it quick and easy to collect relevant therapy data
in one place through a growing number of connected devices,
integrations, and manual entry. Available in 79 countries and 24
languages, mySugr has more than three million registered users. For
more information, please visit www.rochediabetes.com,
www.accu-chek.com and www.mysugr.com.
About Lilly Diabetes
Lilly has been a global leader in
diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research, collaboration and quality
manufacturing we strive to make life better for people affected by
diabetes and related conditions. We work to deliver breakthrough
outcomes through innovative solutions—from medicines and
technologies to support programs and more. For the latest updates,
visit http://www.lillydiabetes.com/ or follow us on Twitter:
@LillyDiabetes and Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global health
care leader that unites caring with discovery to create medicines
that make life better for people around the world. We were founded
more than a century ago by a man committed to creating high-quality
medicines that meet real needs, and today we remain true to that
mission in all our work. Across the globe, Lilly employees work to
discover and bring life-changing medicines to those who need them,
improve the understanding and management of disease, and give back
to communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at lilly.com and
lilly.com/newsroom. P-LLY
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements (as that term is defined in the Private Securities
Litigation Reform Act of 1995) about Lilly's agreements with
Dexcom, Glooko, myDiabby Healthcare and Roche Diabetes Care and
Lilly's diabetes management solutions, including Tempo
Pen™ and Tempo Smart Button™. These
agreements and the Tempo Pen and Tempo Smart Button are part of
Lilly's current and contemplated connected diabetes solutions and
reflect Lilly's current beliefs and expectations. However, as with
any pharmaceutical product or medical device, there are substantial
risks and uncertainties in the process of development and
commercialization. Among other things, there is no guarantee that
Lilly's connected diabetes solutions will be commercially
successful, that Lilly will realize the expected benefits from its
agreements with Dexcom, Glooko, myDiabby Healthcare and Roche, that
the Tempo Smart Button will receive a CE mark or that Lilly will
meet its anticipated timelines for the release of any contemplated
products. For further discussion of these and other risks and
uncertainties, see Lilly's most recent Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
1 International Diabetes Federation. IDF
Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes
Federation, 2019. Available at: http://diabetesatlas.org.
2 Centers for Disease Control and Prevention.
National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and
Prevention, U.S. Dept. of Health and Human Services; 2020.
©Lilly USA, LLC 2021. All
rights reserved.
Refer to:
|
Maggie Pfeiffer;
monson_maggie@lilly.com; +1 (317) 650-5939 (Lilly Media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; +1 (317) 277-1838 (Lilly
Investors)
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-collaborates-internationally-with-leading-diabetes-technology-companies-to-integrate-connected-insulin-pen-solutions-for-people-with-diabetes-301285043.html
SOURCE Eli Lilly and Company